Left Menu
Development News Edition

COVID patients given malaria drug didn't see significant improvements-studies

Reuters | Updated: 15-05-2020 06:03 IST | Created: 15-05-2020 06:03 IST
COVID patients given malaria drug didn't see significant improvements-studies

Patients given the malaria drug touted by President Donald Trump as a potential treatment for COVID-19 did not improve significantly over those who did not, according to two new studies published in the medical journal BMJ on Thursday. Neither trial was placebo controlled, generally considered the gold standard for clinical data.

In a randomized, controlled trial of 150 patients with mild to moderate COVID-19 in China, researchers found that patients on hydroxychloroquine did not get better significantly faster than those not treated with the drug. Adverse events were also higher in patients receiving the malaria drug. An observational study of patients in France found that the drug did not significantly reduce admission to intensive care or death in patients hospitalized with COVID-19 pneumonia who required oxygen. COVID-19 is the disease caused by the novel coronavirus.

Demand for hydroxychloroquine surged after Trump touted it in early April, and U.S. regulators have since authorized its emergency use for coronavirus patients. But the drug has not been proven effective against the disease. Moreover, the U.S. Food and Drug Administration has warned against the use of hydroxychloroquine in COVID-19 patients outside of the hospital or clinical trials due to the risk of serious heart rhythm problems.

The drug is still being widely studied in the United States and abroad as a potential COVID-19 treatment. The National Institutes of Health (NIH) said on Thursday it began a study to evaluate the combination of antibiotic azithromycin and hydroxychloroquine, which Trump described as a potential "game changer" for the pandemic.

The mid-stage study, for which Teva Pharmaceutical Industries Ltd will be donating medicines, will assess whether the combination can prevent hospitalization and death from COVID-19. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is sponsoring the trial, which is being conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG).

"Although there is anecdotal evidence that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes," NIAID Director Anthony Fauci said on Thursday. The NIH's latest study will enroll about 2,000 adults at clinical sites across the country, with many of those expected to be 60 years of age or older or have another condition or chronic disease associated with developing serious complications from COVID-19, such as a cardiovascular disease or diabetes.



Why COVID-19 is unstoppable in USA despite it being ranked at the top of GHS Index?

Several worst-hit countries such as Italy, France, Spain, the UK, Canada, and Russia have peaked COVID-19 cases in April. Almost all of them have gradually flattened the curve. However, the USA is setting new daily records of infections tha...

COVID-19 seems cooking biggest ever global scam

The increasing number of corruption cases on COVID-19 funds from throughout the world and involvement of high profile persons indicate that the countries cant ignore corruption in their pandemic response programs. This has generated the nee...

Health Management Information Systems lack holistic, integrated, and pandemic resilient character

Being a part of the United Nations system, the World Health Organization WHO deserves its share of rebuke for its alleged failure issue COVID-19 health emergency alerts on appropriate time. However, the pandemic has also exposed loopholes i...

Pride in the time of coronavirus: a welcome move online?

This year is different in many ways not least as celebrations are also taking place against the dramatic backdrop of a global health crisis and a resurgence in grassroots activism following the death of George Floyd in Minneapolis. ...


Latest News

With masks and gel, Spaniards vote amid new coronavirus outbreaks

Voters in northern Spain protected themselves with face masks and hand sanitizer before voting on Sunday as Galicia and the Basque Country held regional elections despite new localised outbreaks of COVID-19.The extra health measures meant t...

'Kapoor Haveli' in Pakistan faces demolition threat

The historic ancestral home of late Bollywood actor Rishi Kapoor in Pakistans Peshawar city is facing demolition threat as the current owner of the house is adamant on building a commercial complex on the site worth crores. In 2018, the Pak...

Delhi records 1,573 fresh coronavirus cases, tally rises to 1,12,494; 37 deaths take toll to 3,371: Authorities.

Delhi records 1,573 fresh coronavirus cases, tally rises to 1,12,494 37 deaths take toll to 3,371 Authorities....

Take industry suggestions on proposed tweaking of MMDR Act: Miners' body to govt

Miners body Federation of Indian Mineral Industries FIMI has urged the government to seek suggestions of the companies being hit due to proposed tweaking or removing a particular Section of the mining Act that guarantees seamless transition...

Give Feedback